Senescent skin cells—sometimes dubbed “zombie cells”—have long posed a paradox. These cells, which stop dividing yet refuse ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Iovance Biotherapeutics (NASDAQ: IOVA) is a stock that many investors think has a lot of upside. Iovance's cash burn hasn't ...

One of the greatest innovations benefiting public health was regulation. In the pre-FDA "patent medicine" days, there were ...

Over 2 million Nigerians live with HIV, led by Rivers and Benue. Govt boosts funding for ART access amid rising deaths and gaps in mother-child prevention.

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Declines in drug fatalities are clear public health benefits. However, there is much more work to be done to address drug mortality, including addressing increases in polysubstance use involving ...